Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.29 - $0.64 $71,427 - $157,633
-246,303 Reduced 91.92%
21,654 $6,000
Q4 2022

Feb 14, 2023

BUY
$0.38 - $22.5 $67,394 - $3.99 Million
177,354 Added 195.75%
267,957 $104,000
Q3 2022

Nov 14, 2022

SELL
$0.73 - $23.4 $4,990 - $159,962
-6,836 Reduced 7.02%
90,603 $64,000
Q2 2022

Aug 16, 2022

BUY
$0.66 - $1.81 $42,133 - $115,546
63,838 Added 189.99%
97,439 $79,000
Q1 2022

May 17, 2022

SELL
$1.27 - $2.47 $11,329 - $22,034
-8,921 Reduced 20.98%
33,601 $56,000
Q4 2021

Feb 15, 2022

SELL
$2.21 - $3.22 $329,875 - $480,633
-149,265 Reduced 77.83%
42,522 $100,000
Q3 2021

Nov 16, 2021

SELL
$2.8 - $3.72 $25,981 - $34,517
-9,279 Reduced 4.61%
191,787 $597,000
Q2 2021

Aug 16, 2021

BUY
$2.61 - $4.17 $98,968 - $158,122
37,919 Added 23.24%
201,066 $674,000
Q1 2021

May 18, 2021

BUY
$2.91 - $4.32 $165,328 - $245,436
56,814 Added 53.43%
163,147 $508,000
Q4 2020

Feb 17, 2021

SELL
$2.15 - $3.5 $124,893 - $203,315
-58,090 Reduced 35.33%
106,333 $292,000
Q3 2020

Nov 17, 2020

BUY
$2.77 - $6.17 $227,638 - $507,050
82,180 Added 99.92%
164,423 $470,000
Q2 2020

Aug 17, 2020

BUY
$0.87 - $3.13 $71,551 - $257,420
82,243 New
82,243 $255,000
Q4 2019

Feb 14, 2020

SELL
$0.48 - $1.38 $15,348 - $44,126
-31,976 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$0.47 - $1.05 $54,544 - $121,854
-116,052 Reduced 78.4%
31,976 $15,000
Q2 2019

Aug 15, 2019

BUY
$0.65 - $2.12 $96,218 - $313,819
148,028 New
148,028 $173,000
Q3 2018

Nov 14, 2018

SELL
$1.75 - $2.93 $210,547 - $352,517
-120,313 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$2.75 - $3.85 $330,860 - $463,205
120,313 New
120,313 $331,000

Others Institutions Holding VBIV

About VBI Vaccines Inc


  • Ticker VBIV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 258,256,992
  • Market Cap $5.17M
  • Description
  • VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...
More about VBIV
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.